Kidney Cancer Clinical Trial
— UroCCROfficial title:
UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
NCT number | NCT03293563 |
Other study ID # | CHUBX 2011/38 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 2011 |
Est. completion date | December 2024 |
Within the framework for kidney cancer care, with the recent diversification of treatment modalities of these tumors and the deployment of the concept of multidisciplinary team, it was considered necessary to adapt the research tools to reality of health-care for patients with kidney cancer. UroCCR is the French research network for kidney cancer, funded by the French National Cancer Institute as part of the call for projects for clinical and biological databases (BCB). Depending on the case presentation and disease evolution, more than a thousand of different variables can be recorded. At the same time, biological samples (plasma, urine, healthy and tumor tissues) are collected. This database contains a considerable number of information and high added value since it is the result of multiple expertises that make it not only a multidisciplinary tool but also multicenter, allowing fundamental, translational and clinical research.
Status | Recruiting |
Enrollment | 15000 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patient with kidney cancer - Patient with no opposition to collection of its data for the study Exclusion Criteria: none |
Country | Name | City | State |
---|---|---|---|
France | CHU Angers | Angers | |
France | CHU Bordeaux | Bordeaux | |
France | CHU Caen | Caen | |
France | CHU Henri Mondor - APHP | Créteil | |
France | CHU Grenoble | La Tronche | |
France | Centre Oscar Lambret | Lille | |
France | CHRU Lille | Lille | |
France | CHU Limoges | Limoges | |
France | HCL Lyon | Lyon | |
France | CH St Joseph | Paris | |
France | CHU Kremlin Bicêtre - APHP | Paris | |
France | Hôpital Bichat -APHP | Paris | |
France | Hôpital Européen Georges Pompidou - APHP | Paris | |
France | Hôpital Pitié Salpétrière - APHP | Paris | |
France | Hôpital Tenon - APHP | Paris | |
France | CHU Poitiers | Poitiers | |
France | CHU Reims | Reims | |
France | CHU Rennes - Centre Eugène Marquis | Rennes | |
France | CHU Rouen | Rouen | |
France | CHU Strasbourg | Strasbourg | |
France | CHU Toulouse - Centre Claudius Régaud | Toulouse | |
France | CHRU Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of the rates of complications between radical nephrectomy and partial nephrectomy | Operative time, , | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Primary | Comparison of the rates of complications between radical nephrectomy and partial nephrectomy | Blood loss | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Primary | Comparison of the rates of complications between radical nephrectomy and partial nephrectomy | Clinical scores | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Dosage of creatininemia to assess the renal function after surgery | Dosage of creatininemia | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Dosage of MDRD GFR to assess the renal function after surgery | Dosage of MDRD GFR | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy | Medical or surgical complication rates with Clavien's grading | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy | Medical or surgical complication rates with urinary fistula rate | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy | Medical or surgical complication rates with necessity for nephrectomy or re-exploration | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Safety and efficacy of medical treatment on kidney tumor size evolution | Imaging data: tumor size evolution | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Safety and efficacy of medical treatment on biological parameters | Biological parameters | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years | |
Secondary | Progression of the tumor | Imaging data: tumor location | At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00541008 -
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Recruiting |
NCT00301990 -
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00098943 -
NGR-TNF in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00467077 -
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00089102 -
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00899860 -
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
|
N/A | |
Completed |
NCT00021021 -
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00006968 -
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 |